Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 28

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 28
---
 |                | -3,595 |     |                                              |  -169,674 |     |        |   — |     |  -169,674 |
| As of September 30, 2025                                                    |     |                                              | -48,241 |     |         | -4,509 |     |                                                 |    — |     |                            | 2,605,315 |     |                | -3,595 |     |                                              | 7,130,697 |     |        | 992 |     | 7,131,690 |

<div align='center'>20</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

(5) Condensed Interim Consolidated Statements of Cash Flows

|                                                                                                                     |     | JPY (millions)                       
 Six-month Period Ended September 30, |     2024 |     |     |    2025 |
|:--------------------------------------------------------------------------------------------------------------------|:----|:-------------------------------------|---------:|:----|:----|--------:|
| Cash flows from operating activities:                                                                               |     |                                      |          |     |     |         |
| Net profit for the period                                                                                           |     |                                      |  187,406 |     |     | 112,550 |
| Depreciation and amortization                                                                                       |     |                                      |  384,672 |     |     | 366,618 |
| Impairment losses                                                                                                   |     |                                      |   36,065 |     |     |  87,143 |
| Equity-settled share-based compensation                                                                             |     |                                      |   36,940 |     |     |  35,262 |
| Loss on sales and disposal of property, plant and equipment                                                         |     |                                      |    2,457 |     |     |     916 |
| Gain on divestment of business and subsidiaries                                                                     |     |                                      |   -6,376 |     |     | -17,929 |
| Change in fair value of financial assets and liabilities associated with contingent consideration arrangements, net |     |                                      |    2,172 |     |     |     989 |
| Finance (income) and expenses, net                                                                                  |     |                                      |   93,352 |     |     |  72,142 |
| Share of loss